LFMD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
LifeMD Inc (LFMD) is a good buy for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. The company's strong growth potential in the GLP-1 therapy market, recent product launch, and positive analyst sentiment outweigh the short-term financial challenges. The technical indicators and options data also suggest a positive sentiment, making it a solid entry point.
The MACD histogram is positive and expanding, indicating bullish momentum. The RSI is neutral at 67.511, and moving averages are converging, suggesting potential for upward movement. Key resistance levels are at 4.089 and 4.308, while support levels are at 3.734 and 3.379.
Launch of Foundayo, an oral obesity management medication, expanding LifeMD's GLP-1 therapy portfolio.
Integration with LillyDirect for prescription fulfillment, enhancing patient access.
Analysts have upgraded price targets and ratings, citing growth reacceleration and strong user-retention metrics.
The company's Q4 financials show a significant drop in net income (-435.72% YoY) and EPS (-392.86% YoY), which may concern some investors.
No significant hedge fund or insider trading activity, indicating a lack of strong institutional support.
In Q4 2025, revenue increased by 3.84% YoY to $46.87M, and gross margin improved to 87.14% (+7.04% YoY). However, net income dropped significantly (-435.72% YoY) to $19.19M, and EPS fell by -392.86% YoY to 0.41, reflecting short-term profitability challenges.
Analysts are bullish on LifeMD, with recent upgrades and increased price targets. Mizuho upgraded the stock to Outperform with a price target of $8, citing growth in GLP-1 therapies. Freedom Capital and H.C. Wainwright raised their price targets to $10, highlighting growth reacceleration and strong user-retention metrics.
